The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

@article{Benson2010ThePA,
  title={The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.},
  author={Don Michael Benson and Courtney E. Bakan and Anjali Vinod Mishra and Craig C Hofmeister and Yvonne A Efebera and Brian Becknell and Robert A Baiocchi and Jianying Zhang and Jianhua Yu and Megan Kathleen Smith and Carli N Greenfield and Pierluigi Porcu and Steven Michael Devine and Rinat Rotem-Yehudar and Gerard Lozanski and John C. Byrd and Michael A. Caligiuri},
  journal={Blood},
  year={2010},
  volume={116 13},
  pages={
          2286-94
        }
}
T-cell expression of programmed death receptor-1 (PD-1) down-regulates the immune response against malignancy by interacting with cognate ligands (eg, PD-L1) on tumor cells; however, little is known regarding PD-1 and natural killer (NK) cells. NK cells exert cytotoxicity against multiple myeloma (MM), an effect enhanced through novel therapies. We show that NK cells from MM patients express PD-1 whereas normal NK cells do not and confirm PD-L1 on primary MM cells. Engagement of PD-1 with PD-L1… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 258 CITATIONS, ESTIMATED 58% COVERAGE

Immunotherapy for Pediatric Malignancies

  • Springer International Publishing
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The Influence of Hepatitis C Viral Loads on Natural Killer Cell Function

  • Gastroenterology research
  • 2019
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

  • Averaged 35 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

Preclinical characterization of 1-7F9, a novel human antiKIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

F Romangé, P Andre, P Spee
  • Blood
  • 2009

Cancer statistics, 2007.

  • CA: a cancer journal for clinicians
  • 2007